{"gene":"IKBKB","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1997,"finding":"IKK-beta (IKK-2/IKBKB) was identified as a catalytic subunit of the large IKK signalsome complex purified from HeLa cells. It phosphorylates IκBα and IκBβ in a cytokine-inducible manner, and dominant-negative mutants of IKK-2 blocked RelA nuclear translocation and NF-κB-dependent reporter activity, establishing IKK-2 as a critical kinase in the NF-κB signaling pathway.","method":"Biochemical purification of IKK signalsome from HeLa cells; in vitro kinase assay; dominant-negative mutant overexpression; NF-κB reporter assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical purification, in vitro kinase assay, and dominant-negative mutagenesis in the founding paper; widely replicated","pmids":["9346484"],"is_preprint":false},{"year":1999,"finding":"IKK-beta-deficient mice die at ~E14.5 due to liver degeneration and apoptosis. IKK-beta-deficient embryonic fibroblasts show reduced basal NF-κB activity and impaired cytokine-induced NF-κB activation, and the IKK complex has greatly reduced basal and cytokine-inducible kinase activity. IKK-alpha can only partially compensate for loss of IKK-beta in vivo.","method":"Germline gene knockout in mice; kinase activity assays on IKK complex from KO fibroblasts; NF-κB activity assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype, kinase activity assays, replicated by multiple subsequent studies","pmids":["10229185"],"is_preprint":false},{"year":2000,"finding":"The recombinant IKK1/IKK2 heterodimer has the highest catalytic efficiency (kcat/Km = 47.50 h⁻¹ μM⁻¹) for phosphorylating an IκBα peptide substrate among all IKK isoforms tested. IKK2 homodimer is more active than IKK1 homodimer. Activation loop phosphorylation (mimicked by S177E/S181E mutation) regulates kinase activity; ADP acts as a competitive inhibitor with Ki = 0.77 μM.","method":"Baculoviral expression, purification, and in vitro kinetic characterization of recombinant IKK1/IKK2 heterodimer, homodimers, and constitutively active mutant; IκBα peptide substrate kinase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified recombinant protein, kinetic analysis, and mutagenesis in a single rigorous study","pmids":["10823818"],"is_preprint":false},{"year":2002,"finding":"Epidermis-specific deletion of IKK2 inhibits NF-κB activation in keratinocytes and causes a severe TNF-mediated, αβ T-cell-independent inflammatory skin disease, demonstrating that IKK2-mediated NF-κB activity in epidermal keratinocytes is required for maintaining skin immune homeostasis.","method":"Cre/loxP conditional knockout of IKK2 in epidermal keratinocytes; histological and immunological analysis of skin phenotype","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined cellular phenotype and mechanistic follow-up identifying TNF as mediator; published in high-impact journal","pmids":["12075355"],"is_preprint":false},{"year":2003,"finding":"IKK-beta plays an essential role in LPS-induced phosphorylation of RelA/p65 at serine 536, promoting NF-κB transcriptional activity. IKK-alpha only partially contributes to this phosphorylation. This phosphorylation is independent of the PI3K/Akt pathway.","method":"Mouse embryonic fibroblasts lacking IKK-alpha or IKK-beta; Western blot for p65 Ser536 phosphorylation; reporter assays; LPS stimulation","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO MEFs with defined biochemical readout; two orthogonal methods (Western blot + reporter assay)","pmids":["12759443"],"is_preprint":false},{"year":2003,"finding":"IKK-beta is required for peripheral B cell survival and proliferation. Conditional deletion of IKKbeta in B cells dramatically reduces all peripheral B cell subsets due to cell survival defects, impairs mitogenic responses to LPS, anti-CD40, and anti-IgM, and blocks canonical NF-κB signaling, resulting in failure to mount effective antibody responses.","method":"Conditional KO mice with floxed Ikkbeta allele; flow cytometry; B cell survival and proliferation assays; NF-κB signaling assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with multiple defined phenotypic readouts; clean mechanistic follow-up","pmids":["12707341"],"is_preprint":false},{"year":2004,"finding":"Multiple kinases including IKK-alpha, IKKbeta, IKKε, and TBK1 can phosphorylate p65 at Ser536. IKKε and TBK1 phosphorylate Ser536 in vivo and in vitro. Ser536 phosphorylation promotes IL-8 transcription mediated by TAF(II)31 recruitment to the promoter; absence of phosphorylation favors binding of the corepressor AES to p65.","method":"RNA interference; chromatographic fractionation; dominant-negative mutants; in vitro kinase assay; reconstitution in p65-deficient fibroblasts with phosphomimetic/phosphoblocking mutants; reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assays, in vivo reconstitution with mutagenesis, and multiple orthogonal methods in one study","pmids":["15489227"],"is_preprint":false},{"year":2005,"finding":"IKK-beta is activated in liver by obesity/high-fat diet, and selective hepatocyte-specific constitutive activation of IKK-beta (LIKK mice) causes a type 2 diabetes phenotype with hyperglycemia, hepatic insulin resistance, and systemic insulin resistance via production of proinflammatory cytokines (IL-6, IL-1β, TNF-α). IκBα superrepressor expression in hepatocytes reversed both LIKK and HFD-induced phenotypes. Salicylate inhibition of IKK-beta or IL-6 neutralization improved insulin resistance.","method":"Transgenic mice with constitutively active IKK-beta in hepatocytes; IκBα superrepressor transgenic mice; cytokine neutralization; salicylate pharmacology; glucose/insulin tolerance tests","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models, pharmacological rescue, and cytokine neutralization; replicated across labs","pmids":["15685173"],"is_preprint":false},{"year":2005,"finding":"IKK-beta in myeloid cells activates NF-κB to produce inflammatory mediators that cause systemic insulin resistance. Myeloid-specific IKK-beta knockout mice (Ikbkb∆mye) are protected from high-fat diet, obesity, or aging-induced insulin resistance, whereas hepatocyte-specific knockout (Ikbkb∆hep) retains liver insulin sensitivity but develops peripheral insulin resistance.","method":"Conditional KO mice with myeloid-specific or hepatocyte-specific deletion of Ikbkb; high-fat diet and aging models; insulin sensitivity assays","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple conditional KO models with defined metabolic phenotypes; replicated independently of PMID:15685173","pmids":["15685170"],"is_preprint":false},{"year":2005,"finding":"PDK1 directly phosphorylates IKKbeta at Ser181 in the activation loop, leading to NF-κB nuclear translocation and NF-κB-dependent anti-apoptotic gene expression. This is independent of Akt and IKKα, and constitutively active IKKbeta rescues cells from PDK1 knockdown-mediated TRAIL sensitization.","method":"Kinase screen; in vitro phosphorylation assay; site-specific mutants; IKKα-KO MEFs; siRNA knockdown; NF-κB reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro kinase assay with site identification, but single lab and limited mutagenesis validation described in abstract","pmids":["16207722"],"is_preprint":false},{"year":2005,"finding":"IKK-beta is required for Bcl-2-mediated NF-κB activation in ventricular myocytes. Bcl-2 increases IKK-beta kinase activity (requiring the BH4 domain), and catalytically inactive IKK-beta (but not IKK-alpha) blocks Bcl-2-mediated IκBα phosphorylation and NF-κB activation. This mechanism involves Raf-1/MEKK-1-mediated activation of IKK-beta.","method":"Overexpression of Bcl-2 mutants in ventricular myocytes; kinase activity assay; dominant-negative IKK-beta/alpha; IKKbeta-null MEFs; kinase-defective Raf-1/MEKK-1 mutants","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — kinase activity assay plus KO MEFs and multiple dominant-negatives, single lab","pmids":["12167626"],"is_preprint":false},{"year":2005,"finding":"NIBP (NIK and IKKbeta-binding protein) physically interacts with NIK and IKK-beta but not IKK-alpha or IKK-gamma. NIBP overexpression potentiates TNF-α-induced NF-κB activation through increased phosphorylation of the IKK complex, IκBα, and p65, while NIBP knockdown reduces TNF-α-induced NF-κB activation.","method":"Yeast two-hybrid screen; co-immunoprecipitation; overexpression and siRNA knockdown; NF-κB reporter assay; Western blot for IKK complex phosphorylation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP binding confirmed, functional effects validated by OE and KD, single lab","pmids":["15951441"],"is_preprint":false},{"year":2007,"finding":"IKKbeta physically interacts with TSC1 and phosphorylates it at Ser487 and Ser511, suppressing the TSC1/TSC2 tumor suppressor complex, which activates the mTOR pathway and enhances tumor angiogenesis via VEGF production.","method":"Co-immunoprecipitation; in vitro kinase assay with site-specific phosphorylation; mutant TSC1 overexpression; in vivo tumor models; IHC of tumor specimens for Ser511 phosphorylation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro phosphorylation assay with identified phosphosites, co-IP, and in vivo validation in a high-impact journal","pmids":["17693255"],"is_preprint":false},{"year":2007,"finding":"IEC-intrinsic IKKbeta-dependent gene expression controls intestinal immune homeostasis. IEC-specific IKKbeta deletion reduces epithelial TSLP expression, impairs CD4+ Th2 responses to Trichuris infection, and leads to exacerbated DC-derived IL-12/23p40 and TNF-α and CD4+ T cell-derived IFN-γ and IL-17, causing severe intestinal inflammation.","method":"Cre/loxP conditional KO of IKKbeta in intestinal epithelial cells; parasite infection model; cytokine blockade experiments; T cell transfer","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with multiple defined cellular phenotypes and cytokine blockade rescue; published in Nature","pmids":["17322906"],"is_preprint":false},{"year":2007,"finding":"Constitutive activation of IKK2 in pancreatic acinar cells is sufficient to induce acute pancreatitis in vivo, including edema, inflammatory infiltrates, necrosis, elevated serum lipase, and fibrosis. Dominant-negative IKK2 ameliorated cerulein-induced pancreatitis. TNF-α was identified as a critical effector of IKK2-induced pancreatitis.","method":"Tetracycline-inducible acinar cell-specific expression of constitutively active or dominant-negative IKK2 in transgenic mice; cerulein pancreatitis model; TNF-α inhibition","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional gain- and loss-of-function in same tissue with defined phenotypic outcomes and mechanistic rescue","pmids":["17525799"],"is_preprint":false},{"year":2008,"finding":"IKK1 and IKK2 display distinct collaborative and redundant functions in the liver. Combined conditional ablation of both IKK1 and IKK2 (but not each alone) sensitizes hepatocytes to TNF-induced failure and causes spontaneous fatal cholangitis with inflammatory bile duct destruction. IKK2 alone does not mediate canonical NF-κB in hepatocytes upon TNF stimulation (unlike NEMO), but combined IKK1+IKK2 ablation uncovered redundancy in canonical NF-κB and IKK1-specific functions maintaining bile-blood barrier.","method":"Conditional (hepatocyte-specific) combined KO of IKK1, IKK2, or NEMO; LPS challenge; histological analysis; NF-κB activation assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple conditional KO combinations with clear phenotypic epistasis; mechanistic dissection of redundancy","pmids":["18606991"],"is_preprint":false},{"year":2009,"finding":"Ro52 (an E3 ubiquitin ligase) interacts with phosphorylated/active IKKbeta and, cooperating with the E2 enzyme UbcH5B, monoubiquitinates IKKbeta. This monoubiquitination down-regulates IKKbeta-induced NF-κB signaling and promotes translocation of active IKKbeta to autophagosomes for degradation.","method":"Co-immunoprecipitation; in vitro ubiquitination assay; NF-κB reporter assay; monoubiquitin fusion protein; autophagy inhibitor treatment; subcellular localization imaging","journal":"Journal of biochemistry; Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus in vitro ubiquitination and functional reporter assays; two papers from the same lab","pmids":["19675099","20627395"],"is_preprint":false},{"year":2009,"finding":"PP2A constitutively dephosphorylates and inactivates IKKbeta; UVB irradiation inhibits PP2Ac activity, preventing IKKbeta dephosphorylation and causing persistent IKKbeta activation that phosphorylates newly synthesized IκBα, sustaining NF-κB activation.","method":"Mathematical modeling combined with experimental validation; PP2A activity assays; IKKbeta phosphorylation kinetics; IL-1 and UVB stimulation of cells","journal":"BMC systems biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — experimental-modeling integrated approach; mechanistic identification of PP2A as IKKbeta phosphatase; single lab","pmids":["19607706"],"is_preprint":false},{"year":2009,"finding":"IKK-beta is required in B cells for NF-κB activation and in response to LPS in monocytic cells. A dominant-negative IKK2 mutant, but not wild-type IKK1 or IKK2, inhibited LPS-induced κB-dependent transcription in a dose-dependent manner in human monocytic cells.","method":"Dominant-negative IKK2 overexpression in monocytic cells; κB-dependent reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — dominant-negative approach with functional reporter readout; replicated across multiple labs in different cell types","pmids":["9804806"],"is_preprint":false},{"year":2009,"finding":"IKK-beta is required for activation of both IRF1 and p65 subunit of NF-κB in response to IFN-γ, revealing a novel role for IKKbeta in IFN-γ-dependent chemokine (ip-10) gene expression independent of classical NF-κB activation.","method":"IKKbeta-deficient MEFs; ChIP; reporter assays; IFN-γ and IL-1β stimulation","journal":"Journal of interferon & cytokine research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic KO MEFs with defined molecular readout; single lab, single paper","pmids":["19929594"],"is_preprint":false},{"year":2012,"finding":"IKKbeta directly phosphorylates and activates TSC1 suppression to activate mTOR. In lung cancer, IKK2 promotes tumor proliferation via NF-κB target gene Timp1, which activates the Erk signaling pathway through its receptor CD63. IKK2 depletion reduced tumor proliferation and prolonged survival in a lentiviral lung cancer model.","method":"Lentiviral shRNA knockdown of Ikbkb in mouse lung cancer model; xenograft and lentiviral tumor models; identification of Timp1 as NF-κB target mediator","journal":"Nature cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo lentiviral KD model with survival readout and mechanistic target identification; single lab","pmids":["22327365"],"is_preprint":false},{"year":2012,"finding":"IKK-beta directly interacts with and sequesters FOXO3 in the cytosol, preventing FOXO3 nuclear localization and thereby promoting chemoresistance to cisplatin in MDA-MB-231 breast cancer cells.","method":"Co-immunoprecipitation; overexpression and RNAi knockdown; subcellular fractionation; apoptosis assays","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP interaction plus functional subcellular localization assay and rescue experiments; single lab","pmids":["22313691"],"is_preprint":false},{"year":2012,"finding":"KrasG12D activates AP-1 to induce IL-1α, which in turn activates IKK2/β-NF-κB; NF-κB then induces IL-1α and p62 as feedforward loops sustaining NF-κB activity. Pancreas-targeted IKK2/β inactivation inhibited NF-κB and PDAC development in KrasG12D mice.","method":"Conditional pancreatic IKK2 inactivation in KrasG12D mouse models; analysis of IL-1α/p62 feedforward loops; gene expression and NF-κB activity assays","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo with mechanistic dissection of feedforward loops; published in Cancer Cell","pmids":["22264792"],"is_preprint":false},{"year":2012,"finding":"IKK-beta contributes to H2O2-induced cell death independent of NF-κB, via p85 S6K1. IKK-beta associates with p85 (but not p70) S6K1, which is required for H2O2-induced p85 S6K1 activation, leading to Mdm2 Ser166 phosphorylation and p53 accumulation.","method":"Co-immunoprecipitation; kinase activity assay; siRNA knockdown; phospho-specific Western blot; cell death assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP plus functional rescue; NF-κB-independent mechanism established; single lab","pmids":["22955948"],"is_preprint":false},{"year":2013,"finding":"Hypothalamic IKK-β and NF-κB inhibit GnRH production to mediate aging-related GnRH decline. Prevention of hypothalamic IKK-β and NF-κB activation retards aging and extends lifespan in mice. GnRH treatment amends aging-impaired neurogenesis.","method":"Conditional IKK-β activation/inhibition in hypothalamus using viral vectors; GnRH measurement; lifespan and neurogenesis assays; transgenic mouse models","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple interventional models, mechanistic pathway identification (IKK-β→NF-κB→GnRH suppression), published in Nature","pmids":["23636330"],"is_preprint":false},{"year":2013,"finding":"Loss-of-function IKBKB mutation (c.1292dupG) in humans causes severe combined immunodeficiency with loss of IKK2 expression, resulting in impaired responses to stimulation through T-cell receptors, B-cell receptors, toll-like receptors, inflammatory cytokine receptors, and mitogens in multiple immune cell types.","method":"Homozygosity mapping; whole gene sequencing; functional immune cell stimulation assays; patient lymphocyte studies","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — human loss-of-function genetics with comprehensive multi-receptor functional validation in patient cells","pmids":["24369075"],"is_preprint":false},{"year":2014,"finding":"A nonsense mutation in IKBKB (R286X) causes combined immunodeficiency in humans. Mutant IKKβ(R286X) is unable to complex with IKKα/NEMO, leading to impaired IκBα phosphorylation and NF-κB nuclear translocation in patient B cells.","method":"Whole-exome sequencing; co-immunoprecipitation to test complex formation; Western blot for IκBα phosphorylation; immunofluorescence for NF-κB nuclear translocation","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — human genetics with co-IP, biochemical, and cell-biological mechanistic validation; multi-family study","pmids":["25139357"],"is_preprint":false},{"year":2014,"finding":"IKKβ K171E and K171T mutations found in lymphomas result in constitutively active kinase even in the absence of activation loop phosphorylation. Lysine 171 normally forms part of a cationic pocket interacting with the activation loop phosphate; its mutation disrupts this interaction, causing constitutive activity and contributing to lymphomagenesis.","method":"Biochemical kinase activity assays; predictive structural modeling; TALEN-based knock-in mutagenesis in B lymphoid cells; NF-κB signaling assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay, mutagenesis, structural modeling, and knock-in functional validation in a single study","pmids":["25107905"],"is_preprint":false},{"year":2015,"finding":"Cysteine-46 (Cys-46) is an essential residue for IKK-β kinase activity. Mutation of Cys-46 to alanine (C46A) increases inflammatory responses in vivo in a DTH mouse model. Dihydromyricetin (DMY) binds Cys-46 to exert anti-inflammatory effects in WT but not C46A transgenic mice.","method":"In vitro mutagenesis of IKK-β; C46A transgenic mouse model; delayed-type hypersensitivity model; IKK-β kinase activity assay; pharmacological challenge","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro mutagenesis with in vivo validation in transgenic mouse; mechanistic drug binding site identified; single lab","pmids":["26378659"],"is_preprint":false},{"year":2018,"finding":"A de novo heterozygous gain-of-function IKBKB missense mutation (V203I) causes enhanced NF-κB signaling and combined T and B cell functional defects in humans. CRISPR/Cas9 knock-in of the orthologous codon change in mice recapitulates the human cellular and biochemical phenotype, establishing causation.","method":"Whole exome sequencing; NF-κB signaling assays in patient cells; CRISPR/Cas9 knock-in mouse model; T and B cell functional assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetics with CRISPR knock-in mouse validation recapitulating phenotype; two independent kindreds","pmids":["30337470"],"is_preprint":false},{"year":2020,"finding":"IKK2 mediates LMP1 (Epstein-Barr virus)-induced JNK activation independently of its canonical NF-κB function. LMP1 induces TAK1-mediated NEMO ubiquitination and IKK2 activation, which then activates TPL2 kinase to transmit JNK activation signals. This IKK2-TPL2-JNK axis mediates essential LMP1 survival signals in EBV-transformed B cells.","method":"Genetic knockdown/overexpression; co-immunoprecipitation; kinase activity assays; EBV-transformed B cell models; lymphoma cell line studies","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, kinase assays, and genetic rescue in EBV-transformed cells; identifies a novel IKK2 substrate (TPL2) in JNK pathway","pmids":["32019925"],"is_preprint":false},{"year":2020,"finding":"Paclitaxel activates IKK2 through TLR4 signaling, and IKK2 mediates SNARE-dependent vesicle exocytosis to expose calreticulin on the cell surface, contributing to immunogenic cell death (ICD) in ovarian cancer. This is mechanistically distinct from paclitaxel-induced ER stress signaling.","method":"TLR4 inhibition; IKK2 knockdown; SNARE pathway analysis; CALR surface exposure assay; tumor vaccination assay in vivo","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological dissection of TLR4-IKK2-SNARE pathway with in vitro and in vivo functional assays; single lab","pmids":["32354736"],"is_preprint":false},{"year":2005,"finding":"Deletion of IKK2 specifically in hepatocytes does not impair NF-κB activation or increase apoptosis after TNF-α stimulation (unlike NEMO deletion which blocks NF-κB and causes massive apoptosis), but does protect from ischemia/reperfusion injury.","method":"Conditional hepatocyte-specific KO of IKK2 or NEMO; TNF-α challenge; partial hepatic I/R injury model; NF-κB activation assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with direct comparison to NEMO KO, rigorous biochemical and phenotypic readouts; establishes IKK2 dispensability for hepatocyte NF-κB after TNF","pmids":["15776110"],"is_preprint":false},{"year":2006,"finding":"Muscle-restricted deletion of IKK2 shifts muscle fiber distribution, improves muscle force, protects against denervation-induced atrophy (maintaining fiber type, size, and strength), and facilitates skeletal muscle regeneration through enhanced satellite cell activation and reduced fibrosis.","method":"Conditional muscle-specific KO of IKK2; denervation model; muscle damage/regeneration model; force measurement; protein synthesis/degradation assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with multiple defined functional and molecular phenotypes; mechanistic protein synthesis/degradation readouts","pmids":["17080195"],"is_preprint":false}],"current_model":"IKBKB (IKK-beta/IKK2) is the primary catalytic serine/threonine kinase subunit of the IKK signalsome complex that phosphorylates IκBα/β at specific serines to trigger their ubiquitination and proteasomal degradation, releasing and activating NF-κB transcription factors; beyond canonical IκB phosphorylation, IKKbeta directly phosphorylates additional substrates including TSC1 (activating mTOR), p85 S6K1 (mediating oxidative stress-induced cell death), and p65/RelA at Ser536 (enhancing transcriptional activity), is itself regulated by upstream kinases (PDK1 phosphorylates Ser181) and by Ro52-mediated monoubiquitination directing it to autophagosomal degradation, and has essential tissue-specific roles in B and T cell activation, skin and intestinal immune homeostasis, hepatic and systemic metabolic regulation, muscle homeostasis, and hypothalamic control of aging and blood pressure—all operating primarily, though not exclusively, through NF-κB-dependent transcription."},"narrative":{"mechanistic_narrative":"IKBKB (IKK-beta/IKK2) is the principal catalytic serine/threonine kinase of the multiprotein IKK signalsome that drives canonical NF-κB activation by phosphorylating IκBα and IκBβ in a cytokine-inducible manner, triggering their degradation and releasing RelA for nuclear translocation [PMID:9346484]. It is the dominant catalytic isoform: the IKK1/IKK2 heterodimer is the most kinetically efficient configuration for IκBα phosphorylation, its activity is gated by activation-loop phosphorylation at Ser177/Ser181, and germline loss causes embryonic lethality from hepatic apoptosis with only partial compensation by IKK-alpha [PMID:10229185, PMID:10823818]. Beyond IκB, IKK2 amplifies NF-κB output by directly phosphorylating RelA/p65 at Ser536 to promote coactivator recruitment and transcription [PMID:12759443, PMID:15489227], and it extends into NF-κB-independent signaling by phosphorylating TSC1 (at Ser487/Ser511) to activate mTOR and angiogenesis [PMID:17693255], by associating with p85 S6K1 to drive H2O2-induced p53-dependent death [PMID:22955948], and by activating a TPL2-JNK survival axis downstream of EBV LMP1 [PMID:32019925]. Its activity is set by upstream kinases including PDK1 (Ser181) [PMID:16207722] and constrained by PP2A-mediated dephosphorylation [PMID:19607706] and Ro52-mediated monoubiquitination that targets active IKK2 to autophagosomes [PMID:19675099, PMID:20627395]. Tissue-restricted genetic studies establish non-redundant roles in epidermal and intestinal immune homeostasis [PMID:12075355, PMID:17322906], peripheral B-cell survival [PMID:12707341], hepatic and myeloid-driven metabolic control of insulin resistance [PMID:15685173, PMID:15685170], skeletal muscle homeostasis [PMID:17080195], and hypothalamic NF-κB control of GnRH and aging [PMID:23636330], while constitutive IKK2 activity contributes to pancreatitis and Kras-driven and lymphoid malignancy [PMID:17525799, PMID:22264792, PMID:25107905]. In humans, both loss-of-function and gain-of-function IKBKB mutations cause combined immunodeficiency, directly linking IKK2 kinase activity and complex assembly to immune cell signaling [PMID:24369075, PMID:25139357, PMID:30337470].","teleology":[{"year":1997,"claim":"Established that IKK2 is a catalytic kinase subunit physically driving cytokine-induced NF-κB activation, defining the core of the canonical pathway.","evidence":"Biochemical purification of the IKK signalsome from HeLa cells with in vitro kinase assays and dominant-negative mutants","pmids":["9346484"],"confidence":"High","gaps":["Did not resolve isoform-specific contributions of IKK1 vs IKK2","Upstream activating kinases not yet defined"]},{"year":1999,"claim":"Demonstrated IKK2 is non-redundant in vivo for NF-κB-dependent hepatocyte survival, showing IKK-alpha cannot fully compensate.","evidence":"Germline knockout mice with kinase activity and NF-κB assays in KO fibroblasts","pmids":["10229185"],"confidence":"High","gaps":["Embryonic lethality precluded analysis of adult tissue-specific roles","Mechanism of partial IKK-alpha compensation unresolved"]},{"year":2000,"claim":"Quantified the biochemical basis for IKK2 dominance by showing the IKK1/IKK2 heterodimer is the most efficient IκBα kinase and that activation-loop phosphorylation governs activity.","evidence":"Recombinant baculoviral expression and in vitro kinetic characterization with phosphomimetic mutants","pmids":["10823818"],"confidence":"High","gaps":["Kinetics on peptide substrate may not reflect full-length IκB or in-cell regulation","Did not address substrates beyond IκBα"]},{"year":2003,"claim":"Extended IKK2 function beyond IκB to direct phosphorylation of RelA/p65 at Ser536, showing it shapes NF-κB transcriptional output, not just nuclear entry.","evidence":"IKK-alpha/IKK-beta KO MEFs with phospho-specific Western blot and reporter assays under LPS stimulation","pmids":["12759443"],"confidence":"High","gaps":["Relative in vivo contribution of multiple Ser536 kinases not resolved","Promoter-context dependence not addressed"]},{"year":2004,"claim":"Clarified the transcriptional consequence of Ser536 phosphorylation by linking it to coactivator (TAF II 31) versus corepressor (AES) recruitment at target promoters.","evidence":"RNAi, in vitro kinase assays, and reconstitution of p65-deficient fibroblasts with phosphomimetic/blocking mutants plus reporter assays","pmids":["15489227"],"confidence":"High","gaps":["Multiple kinases (IKKε, TBK1) also phosphorylate Ser536, complicating IKK2-specific attribution","Genome-wide target scope not defined"]},{"year":2005,"claim":"Defined upstream and counter-regulatory inputs on IKK2 activity: PDK1 phosphorylates Ser181 to promote survival signaling, and converging Raf-1/MEKK-1 and Bcl-2 inputs activate IKK2.","evidence":"Kinase screens, in vitro phosphorylation, site-specific and dominant-negative mutants, IKKα-KO MEFs, and ventricular myocyte overexpression","pmids":["16207722","12167626"],"confidence":"Medium","gaps":["PDK1-IKK2 link based on a single lab with limited mutagenesis","Physiological context of Bcl-2-IKK2 coupling beyond myocytes unclear"]},{"year":2005,"claim":"Established IKK2 as a central node coupling inflammation to metabolic disease, with distinct hepatocyte- versus myeloid-intrinsic contributions to insulin resistance.","evidence":"Hepatocyte-constitutive-active, hepatocyte-KO, and myeloid-KO mouse models with IκBα superrepressor rescue, cytokine neutralization, and salicylate pharmacology","pmids":["15685173","15685170"],"confidence":"High","gaps":["Direct metabolic substrates of IKK2 distinct from NF-κB cytokine output not defined","Relative cross-tissue weighting in human disease not addressed"]},{"year":2005,"claim":"Identified phosphatase and adaptor control of IKK2: PP2A constitutively inactivates IKK2 and is itself suppressed by UVB to sustain signaling, while NIBP potentiates IKK complex phosphorylation.","evidence":"PP2A activity assays with modeling, IL-1/UVB stimulation, and yeast two-hybrid plus Co-IP/knockdown for NIBP","pmids":["19607706","15951441"],"confidence":"Medium","gaps":["NIBP interaction validated in a single lab without reciprocal in vivo evidence","PP2A regulation studied via modeling-experiment integration in limited cell contexts"]},{"year":2007,"claim":"Uncovered the first major NF-κB-independent substrate axis by showing IKK2 phosphorylates TSC1 (Ser487/Ser511) to suppress the TSC complex and activate mTOR, linking inflammation to growth and angiogenesis.","evidence":"Co-IP, in vitro kinase assays with phosphosite identification, mutant overexpression, in vivo tumor models, and tumor IHC","pmids":["17693255"],"confidence":"High","gaps":["Quantitative contribution of TSC1 phosphorylation to mTOR activity in normal tissues unresolved"]},{"year":2007,"claim":"Demonstrated tissue-intrinsic IKK2 requirements for epithelial immune homeostasis in intestine and the sufficiency of IKK2 activation to drive pancreatitis.","evidence":"Intestinal epithelial and pancreatic acinar conditional gain/loss-of-function mouse models with infection, cytokine blockade, and cerulein challenge","pmids":["17322906","17525799"],"confidence":"High","gaps":["Downstream IKK2-dependent gene programs only partially mapped","TNF identified as effector but full mediator network undefined"]},{"year":2008,"claim":"Dissected hepatic IKK isoform logic, showing IKK2 alone is dispensable for hepatocyte canonical NF-κB after TNF but redundant with IKK1, which maintains the bile-blood barrier.","evidence":"Combined and single hepatocyte-specific conditional KO of IKK1, IKK2, and NEMO with LPS challenge and histology","pmids":["18606991","15776110"],"confidence":"High","gaps":["Molecular basis of IKK1/IKK2 redundancy in hepatocytes not defined","Substrate-level explanation for NEMO vs IKK2 divergence unresolved"]},{"year":2009,"claim":"Defined a degradative off-switch in which Ro52, with UbcH5B, monoubiquitinates active IKK2 to dampen NF-κB and route it to autophagosomes.","evidence":"Co-IP, in vitro ubiquitination, monoubiquitin fusions, autophagy inhibition, and localization imaging","pmids":["19675099","20627395"],"confidence":"Medium","gaps":["Both reports from the same lab","Physiological triggers controlling Ro52-IKK2 engagement unclear"]},{"year":2012,"claim":"Broadened IKK2 effector outputs beyond IκB to FOXO3 cytosolic sequestration, p85-S6K1-driven oxidative death, and Kras-NF-κB feedforward loops sustaining tumorigenesis.","evidence":"Co-IP, knockdown/overexpression, subcellular fractionation, kinase assays, and conditional pancreatic IKK2 inactivation in KrasG12D mice","pmids":["22313691","22955948","22264792","22327365"],"confidence":"Medium","gaps":["FOXO3 and S6K1 interactions rest on single-lab Co-IP without structural detail","Direct vs indirect nature of several effector links not fully separated"]},{"year":2013,"claim":"Revealed a systemic physiological role for hypothalamic IKK-β/NF-κB in suppressing GnRH to drive aging, identifying it as a modulator of lifespan and neurogenesis.","evidence":"Viral hypothalamic IKK-β activation/inhibition, transgenic mice, GnRH measurement, and lifespan/neurogenesis assays","pmids":["23636330"],"confidence":"High","gaps":["Direct molecular link from NF-κB to GnRH repression not defined","Neuronal-specific IKK2 substrates unidentified"]},{"year":2014,"claim":"Established human IKBKB disease causation through loss-of-function mutations causing combined immunodeficiency via failed complex assembly and impaired IκBα phosphorylation.","evidence":"Whole-exome sequencing, Co-IP for complex formation, IκBα phospho-blots, and NF-κB translocation in patient cells","pmids":["24369075","25139357"],"confidence":"High","gaps":["Genotype-phenotype range across mutation types incompletely mapped"]},{"year":2014,"claim":"Defined structural determinants of IKK2 catalysis by showing K171 mutations disrupt activation-loop phosphate coordination to yield constitutive, oncogenic kinase activity.","evidence":"Biochemical kinase assays, structural modeling, and TALEN knock-in in B lymphoid cells","pmids":["25107905"],"confidence":"High","gaps":["No high-resolution structure of the mutant confirming the proposed cationic pocket"]},{"year":2018,"claim":"Demonstrated that gain-of-function IKBKB mutation causes human immune disease through enhanced NF-κB signaling, formally proving causation in vivo.","evidence":"Whole-exome sequencing, patient-cell NF-κB assays, and CRISPR/Cas9 knock-in mice recapitulating phenotype","pmids":["30337470"],"confidence":"High","gaps":["Mechanism by which V203I enhances activity at the structural level not resolved"]},{"year":2020,"claim":"Expanded IKK2 signaling repertoire to NF-κB-independent outputs: a TPL2-JNK survival axis downstream of EBV LMP1 and SNARE-dependent calreticulin exposure for immunogenic cell death.","evidence":"Co-IP, kinase assays, genetic rescue in EBV-transformed B cells, and TLR4/IKK2/SNARE dissection with CALR surface assays","pmids":["32019925","32354736"],"confidence":"High","gaps":["Direct IKK2 substrate in the SNARE/exocytosis pathway not identified","Generality of IKK2-TPL2-JNK axis beyond EBV context unclear"]},{"year":null,"claim":"How IKK2 substrate selection is partitioned between canonical IκB/NF-κB signaling and the growing set of NF-κB-independent substrates (TSC1, S6K1, TPL2, FOXO3) in a context-dependent manner remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model for substrate switching","Stoichiometry and structural basis of non-canonical substrate engagement undefined","In vivo relevance of several effector axes outside disease models untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,4,12,23]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,12,27]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,4,24]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[21,23]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,9,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,5,13,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,4,6]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[22,25,27,29]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[7,8]}],"complexes":["IKK signalsome (IKK complex)"],"partners":["IKBKA","IKBKG","NIK","TSC1","RPS6KB1","FOXO3","NIBP","TRIM21"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O14920","full_name":"Inhibitor of nuclear factor kappa-B kinase subunit beta","aliases":["I-kappa-B kinase 2","IKK-2","IKK2","Nuclear factor NF-kappa-B inhibitor kinase beta","NFKBIKB","Serine/threonine protein kinase IKBKB"],"length_aa":756,"mass_kda":86.6,"function":"Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses (PubMed:20434986, PubMed:20797629, PubMed:21138416, PubMed:30337470, PubMed:9346484). Acts as a part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation (PubMed:9346484). Phosphorylates inhibitors of NF-kappa-B on 2 critical serine residues (PubMed:20434986, PubMed:20797629, PubMed:21138416, PubMed:9346484). These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome (PubMed:20434986, PubMed:20797629, PubMed:21138416, PubMed:9346484). In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis (PubMed:20434986, PubMed:20797629, PubMed:21138416, PubMed:9346484). In addition to the NF-kappa-B inhibitors, phosphorylates several other components of the signaling pathway including NEMO/IKBKG, NF-kappa-B subunits RELA and NFKB1, as well as IKK-related kinases TBK1 and IKBKE (PubMed:11297557, PubMed:14673179, PubMed:20410276, PubMed:21138416). IKK-related kinase phosphorylations may prevent the overproduction of inflammatory mediators since they exert a negative regulation on canonical IKKs (PubMed:11297557, PubMed:20410276, PubMed:21138416). Phosphorylates FOXO3, mediating the TNF-dependent inactivation of this pro-apoptotic transcription factor (PubMed:15084260). Also phosphorylates other substrates including NAA10, NCOA3, BCL10 and IRS1 (PubMed:17213322, PubMed:19716809). Phosphorylates RIPK1 at 'Ser-25' which represses its kinase activity and consequently prevents TNF-mediated RIPK1-dependent cell death (By similarity). Phosphorylates the C-terminus of IRF5, stimulating IRF5 homodimerization and translocation into the nucleus (PubMed:25326418). Following bacterial lipopolysaccharide (LPS)-induced TLR4 endocytosis, phosphorylates STAT1 at 'Thr-749' which restricts interferon signaling and anti-inflammatory responses and promotes innate inflammatory responses (PubMed:38621137). IKBKB-mediated phosphorylation of STAT1 at 'Thr-749' promotes binding of STAT1 to the ARID5A promoter, resulting in transcriptional activation of ARID5A and subsequent ARID5A-mediated stabilization of IL6 (PubMed:32209697). It also promotes binding of STAT1 to the IL12B promoter and activation of IL12B transcription (PubMed:32209697)","subcellular_location":"Cytoplasm; Nucleus; Membrane raft","url":"https://www.uniprot.org/uniprotkb/O14920/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IKBKB","classification":"Not Classified","n_dependent_lines":52,"n_total_lines":1208,"dependency_fraction":0.04304635761589404},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000104365","cell_line_id":"CID001186","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":2}],"interactors":[{"gene":"CHUK","stoichiometry":10.0},{"gene":"IKBKG","stoichiometry":10.0},{"gene":"FKBP5","stoichiometry":0.2},{"gene":"CDC37","stoichiometry":0.2},{"gene":"NFKB1","stoichiometry":0.2},{"gene":"RELA","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001186","total_profiled":1310},"omim":[{"mim_id":"619368","title":"LEUCINE-RICH REPEAT-CONTAINING PROTEIN 14; LRRC14","url":"https://www.omim.org/entry/619368"},{"mim_id":"619309","title":"PROTEIN PHOSPHATASE, MAGNESIUM/MANGANESE-DEPENDENT, 1F; PPM1F","url":"https://www.omim.org/entry/619309"},{"mim_id":"618204","title":"IMMUNODEFICIENCY 15A; IMD15A","url":"https://www.omim.org/entry/618204"},{"mim_id":"617464","title":"UNC5 FAMILY C-TERMINAL-LIKE PROTEIN; UNC5CL","url":"https://www.omim.org/entry/617464"},{"mim_id":"616452","title":"B-CELL EXPANSION WITH NFKB AND T-CELL ANERGY; BENTA","url":"https://www.omim.org/entry/616452"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/IKBKB"},"hgnc":{"alias_symbol":["IKK2","NFKBIKB","IKK-beta","IKKB"],"prev_symbol":[]},"alphafold":{"accession":"O14920","domains":[{"cath_id":"3.30.200.20","chopping":"11-99","consensus_level":"medium","plddt":89.7553,"start":11,"end":99},{"cath_id":"1.10.510.10","chopping":"102-308","consensus_level":"high","plddt":92.3246,"start":102,"end":308},{"cath_id":"3.10.20.90","chopping":"311-395","consensus_level":"medium","plddt":93.4679,"start":311,"end":395}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14920","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14920-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14920-F1-predicted_aligned_error_v6.png","plddt_mean":86.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IKBKB","jax_strain_url":"https://www.jax.org/strain/search?query=IKBKB"},"sequence":{"accession":"O14920","fasta_url":"https://rest.uniprot.org/uniprotkb/O14920.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14920/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14920"}},"corpus_meta":[{"pmid":"15685173","id":"PMC_15685173","title":"Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB.","date":"2005","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15685173","citation_count":1802,"is_preprint":false},{"pmid":"9346484","id":"PMC_9346484","title":"IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9346484","citation_count":1786,"is_preprint":false},{"pmid":"15685170","id":"PMC_15685170","title":"IKK-beta links inflammation to obesity-induced insulin resistance.","date":"2005","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15685170","citation_count":1444,"is_preprint":false},{"pmid":"23636330","id":"PMC_23636330","title":"Hypothalamic programming of systemic ageing involving IKK-β, NF-κB and GnRH.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23636330","citation_count":685,"is_preprint":false},{"pmid":"17693255","id":"PMC_17693255","title":"IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17693255","citation_count":545,"is_preprint":false},{"pmid":"10229185","id":"PMC_10229185","title":"Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice.","date":"1999","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10229185","citation_count":476,"is_preprint":false},{"pmid":"22264792","id":"PMC_22264792","title":"KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.","date":"2012","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/22264792","citation_count":432,"is_preprint":false},{"pmid":"17322906","id":"PMC_17322906","title":"Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis.","date":"2007","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/17322906","citation_count":422,"is_preprint":false},{"pmid":"12075355","id":"PMC_12075355","title":"TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12075355","citation_count":389,"is_preprint":false},{"pmid":"14704745","id":"PMC_14704745","title":"Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance.","date":"2003","source":"International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity","url":"https://pubmed.ncbi.nlm.nih.gov/14704745","citation_count":352,"is_preprint":false},{"pmid":"12759443","id":"PMC_12759443","title":"IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12759443","citation_count":341,"is_preprint":false},{"pmid":"15489227","id":"PMC_15489227","title":"Constitutive and interleukin-1-inducible phosphorylation of p65 NF-{kappa}B at serine 536 is mediated by multiple protein kinases including I{kappa}B kinase (IKK)-{alpha}, IKK{beta}, IKK{epsilon}, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15489227","citation_count":317,"is_preprint":false},{"pmid":"17080195","id":"PMC_17080195","title":"Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration.","date":"2006","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17080195","citation_count":262,"is_preprint":false},{"pmid":"18308615","id":"PMC_18308615","title":"IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB.","date":"2008","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18308615","citation_count":199,"is_preprint":false},{"pmid":"21642978","id":"PMC_21642978","title":"Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-β and NF-κB.","date":"2011","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21642978","citation_count":194,"is_preprint":false},{"pmid":"32354736","id":"PMC_32354736","title":"Paclitaxel Induces Immunogenic Cell Death in Ovarian Cancer via TLR4/IKK2/SNARE-Dependent Exocytosis.","date":"2020","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/32354736","citation_count":154,"is_preprint":false},{"pmid":"12707341","id":"PMC_12707341","title":"IKK beta is required for peripheral B cell survival and proliferation.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12707341","citation_count":153,"is_preprint":false},{"pmid":"9804806","id":"PMC_9804806","title":"Role of IKK1 and IKK2 in lipopolysaccharide signaling in human monocytic cells.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9804806","citation_count":153,"is_preprint":false},{"pmid":"15776110","id":"PMC_15776110","title":"Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury.","date":"2005","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/15776110","citation_count":150,"is_preprint":false},{"pmid":"24369075","id":"PMC_24369075","title":"Deficiency of innate and acquired immunity caused by an IKBKB mutation.","date":"2013","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24369075","citation_count":147,"is_preprint":false},{"pmid":"12140289","id":"PMC_12140289","title":"IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic Gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12140289","citation_count":140,"is_preprint":false},{"pmid":"15753951","id":"PMC_15753951","title":"A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity.","date":"2005","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15753951","citation_count":133,"is_preprint":false},{"pmid":"22327365","id":"PMC_22327365","title":"Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.","date":"2012","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/22327365","citation_count":115,"is_preprint":false},{"pmid":"15951441","id":"PMC_15951441","title":"NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15951441","citation_count":104,"is_preprint":false},{"pmid":"16413924","id":"PMC_16413924","title":"FDC-specific functions of p55TNFR and IKK2 in the development of FDC networks and of antibody responses.","date":"2006","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/16413924","citation_count":102,"is_preprint":false},{"pmid":"17525799","id":"PMC_17525799","title":"Constitutive IKK2 activation in acinar cells is sufficient to induce pancreatitis in vivo.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17525799","citation_count":101,"is_preprint":false},{"pmid":"20627395","id":"PMC_20627395","title":"Downregulation of active IKK beta by Ro52-mediated autophagy.","date":"2010","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20627395","citation_count":93,"is_preprint":false},{"pmid":"11483407","id":"PMC_11483407","title":"Tumor necrosis factor alpha-induced activation of downstream NF-kappaB site of the promoter mediates epithelial ICAM-1 expression and monocyte adhesion. Involvement of PKCalpha, tyrosine kinase, and IKK2, but not MAPKs, pathway.","date":"2001","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/11483407","citation_count":90,"is_preprint":false},{"pmid":"21701067","id":"PMC_21701067","title":"Constitutive IKK2 activation in intestinal epithelial cells induces intestinal tumors in mice.","date":"2011","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21701067","citation_count":89,"is_preprint":false},{"pmid":"24550137","id":"PMC_24550137","title":"MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.","date":"2014","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24550137","citation_count":88,"is_preprint":false},{"pmid":"23740840","id":"PMC_23740840","title":"miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.","date":"2013","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23740840","citation_count":83,"is_preprint":false},{"pmid":"20530876","id":"PMC_20530876","title":"Conditional ablation of Ikkb inhibits melanoma tumor development in mice.","date":"2010","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20530876","citation_count":81,"is_preprint":false},{"pmid":"16207722","id":"PMC_16207722","title":"3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase beta (IkkB) phosphorylation activates NF-kappaB signaling.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16207722","citation_count":79,"is_preprint":false},{"pmid":"18606991","id":"PMC_18606991","title":"IKK1 and IKK2 cooperate to maintain bile duct integrity in the liver.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18606991","citation_count":79,"is_preprint":false},{"pmid":"12617920","id":"PMC_12617920","title":"Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1.","date":"2003","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/12617920","citation_count":79,"is_preprint":false},{"pmid":"15225718","id":"PMC_15225718","title":"Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents.","date":"2004","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/15225718","citation_count":75,"is_preprint":false},{"pmid":"18408102","id":"PMC_18408102","title":"Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.","date":"2008","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/18408102","citation_count":74,"is_preprint":false},{"pmid":"29332242","id":"PMC_29332242","title":"Selective IKK2 inhibitor IMD0354 disrupts NF-κB signaling to suppress corneal inflammation and angiogenesis.","date":"2018","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/29332242","citation_count":71,"is_preprint":false},{"pmid":"29187362","id":"PMC_29187362","title":"IKK2/NF-κB signaling protects neurons after traumatic brain injury.","date":"2018","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/29187362","citation_count":68,"is_preprint":false},{"pmid":"24755559","id":"PMC_24755559","title":"miR-200c regulates IL8 expression by targeting IKBKB: a potential mediator of inflammation in leiomyoma pathogenesis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24755559","citation_count":68,"is_preprint":false},{"pmid":"14603259","id":"PMC_14603259","title":"AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14603259","citation_count":68,"is_preprint":false},{"pmid":"19675099","id":"PMC_19675099","title":"Ro52-mediated monoubiquitination of IKK{beta} down-regulates NF-{kappa}B signalling.","date":"2009","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19675099","citation_count":66,"is_preprint":false},{"pmid":"30337470","id":"PMC_30337470","title":"Gain-of-function IKBKB mutation causes human combined immune deficiency.","date":"2018","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30337470","citation_count":65,"is_preprint":false},{"pmid":"16687566","id":"PMC_16687566","title":"Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle.","date":"2006","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16687566","citation_count":60,"is_preprint":false},{"pmid":"25139357","id":"PMC_25139357","title":"A nonsense mutation in IKBKB causes combined immunodeficiency.","date":"2014","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25139357","citation_count":57,"is_preprint":false},{"pmid":"10823818","id":"PMC_10823818","title":"Characterization of the recombinant IKK1/IKK2 heterodimer. Mechanisms regulating kinase activity.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10823818","citation_count":57,"is_preprint":false},{"pmid":"12167626","id":"PMC_12167626","title":"IKK beta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12167626","citation_count":57,"is_preprint":false},{"pmid":"17502144","id":"PMC_17502144","title":"The discovery of 2-amino-3,5-diarylbenzamide inhibitors of IKK-alpha and IKK-beta kinases.","date":"2007","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/17502144","citation_count":55,"is_preprint":false},{"pmid":"19168710","id":"PMC_19168710","title":"A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.","date":"2009","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19168710","citation_count":55,"is_preprint":false},{"pmid":"16604092","id":"PMC_16604092","title":"Rosmarinic acid as a downstream inhibitor of IKK-beta in TNF-alpha-induced upregulation of CCL11 and CCR3.","date":"2006","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16604092","citation_count":53,"is_preprint":false},{"pmid":"19628709","id":"PMC_19628709","title":"The IKK2/NF-{kappa}B pathway suppresses MYC-induced lymphomagenesis.","date":"2009","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/19628709","citation_count":48,"is_preprint":false},{"pmid":"16517756","id":"PMC_16517756","title":"IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic.","date":"2006","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16517756","citation_count":45,"is_preprint":false},{"pmid":"15225717","id":"PMC_15225717","title":"Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: Improvement of in vitro activity.","date":"2004","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/15225717","citation_count":45,"is_preprint":false},{"pmid":"17542984","id":"PMC_17542984","title":"Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.","date":"2007","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/17542984","citation_count":43,"is_preprint":false},{"pmid":"20463356","id":"PMC_20463356","title":"Tumor necrosis factor stimulates matrix metalloproteinase 9 secretion from cultured human chorionic trophoblast cells through TNF receptor 1 signaling to IKBKB-NFKB and MAPK1/3 pathway.","date":"2010","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/20463356","citation_count":43,"is_preprint":false},{"pmid":"29434332","id":"PMC_29434332","title":"The p55TNFR-IKK2-Ripk3 axis orchestrates arthritis by regulating death and inflammatory pathways in synovial fibroblasts.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29434332","citation_count":42,"is_preprint":false},{"pmid":"29410383","id":"PMC_29410383","title":"Concentrated Ambient PM2.5-Induced Inflammation and Endothelial Dysfunction in a Murine Model of Neural IKK2 Deficiency.","date":"2018","source":"Environmental health perspectives","url":"https://pubmed.ncbi.nlm.nih.gov/29410383","citation_count":42,"is_preprint":false},{"pmid":"19607706","id":"PMC_19607706","title":"Mechanism of PP2A-mediated IKK beta dephosphorylation: a systems biological approach.","date":"2009","source":"BMC systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/19607706","citation_count":41,"is_preprint":false},{"pmid":"21078555","id":"PMC_21078555","title":"Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques.","date":"2010","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/21078555","citation_count":40,"is_preprint":false},{"pmid":"38652539","id":"PMC_38652539","title":"miRNA-148a-containing GMSC-derived EVs modulate Treg/Th17 balance via IKKB/NF-κB pathway and treat a rheumatoid arthritis model.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/38652539","citation_count":39,"is_preprint":false},{"pmid":"30661291","id":"PMC_30661291","title":"RPS15A promotes gastric cancer progression via activation of the Akt/IKK-β/NF-κB signalling pathway.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30661291","citation_count":39,"is_preprint":false},{"pmid":"19929594","id":"PMC_19929594","title":"Roles of IKK-beta, IRF1, and p65 in the activation of chemokine genes by interferon-gamma.","date":"2009","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/19929594","citation_count":39,"is_preprint":false},{"pmid":"17070604","id":"PMC_17070604","title":"Targeting the NF-kappaB pathway through pharmacological inhibition of IKK2 prevents human cytomegalovirus replication and virus-induced inflammatory response in infected endothelial cells.","date":"2006","source":"Antiviral research","url":"https://pubmed.ncbi.nlm.nih.gov/17070604","citation_count":39,"is_preprint":false},{"pmid":"20537930","id":"PMC_20537930","title":"IKK-beta inhibitors: an analysis of drug-receptor interaction by using molecular docking and pharmacophore 3D-QSAR approaches.","date":"2010","source":"Journal of molecular graphics & modelling","url":"https://pubmed.ncbi.nlm.nih.gov/20537930","citation_count":37,"is_preprint":false},{"pmid":"26993770","id":"PMC_26993770","title":"MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26993770","citation_count":36,"is_preprint":false},{"pmid":"24296718","id":"PMC_24296718","title":"Long-term IKK2/NF-κB signaling in pancreatic β-cells induces immune-mediated diabetes.","date":"2013","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/24296718","citation_count":36,"is_preprint":false},{"pmid":"31549412","id":"PMC_31549412","title":"miR-218 regulates diabetic nephropathy via targeting IKK-β and modulating NK-κB-mediated inflammation.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/31549412","citation_count":36,"is_preprint":false},{"pmid":"12762338","id":"PMC_12762338","title":"Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-beta kinase pathway.","date":"2003","source":"The European respiratory journal","url":"https://pubmed.ncbi.nlm.nih.gov/12762338","citation_count":36,"is_preprint":false},{"pmid":"26433127","id":"PMC_26433127","title":"A negative feedback loop between miR-200b and the nuclear factor-κB pathway via IKBKB/IKK-β in breast cancer cells.","date":"2016","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/26433127","citation_count":35,"is_preprint":false},{"pmid":"26219821","id":"PMC_26219821","title":"Moderate activation of IKK2-NF-kB in unstressed adult mouse liver induces cytoprotective genes and lipogenesis without apparent signs of inflammation or fibrosis.","date":"2015","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/26219821","citation_count":35,"is_preprint":false},{"pmid":"16942442","id":"PMC_16942442","title":"Amelioration of arthritis by intraarticular dominant negative Ikk beta gene therapy using adeno-associated virus type 5.","date":"2006","source":"Human gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16942442","citation_count":34,"is_preprint":false},{"pmid":"28193238","id":"PMC_28193238","title":"Transient IKK2 activation in astrocytes initiates selective non-cell-autonomous neurodegeneration.","date":"2017","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/28193238","citation_count":33,"is_preprint":false},{"pmid":"28278500","id":"PMC_28278500","title":"Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28278500","citation_count":33,"is_preprint":false},{"pmid":"16374504","id":"PMC_16374504","title":"Tumour necrosis factor-alpha depletes histone deacetylase 1 protein through IKK2.","date":"2005","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/16374504","citation_count":32,"is_preprint":false},{"pmid":"30818064","id":"PMC_30818064","title":"Genetic suppression of IKK2/NF-κB in astrocytes inhibits neuroinflammation and reduces neuronal loss in the MPTP-Probenecid model of Parkinson's disease.","date":"2019","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30818064","citation_count":31,"is_preprint":false},{"pmid":"34685649","id":"PMC_34685649","title":"IKK2/NF-κB Activation in Astrocytes Reduces amyloid β Deposition: A Process Associated with Specific Microglia Polarization.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34685649","citation_count":30,"is_preprint":false},{"pmid":"30543861","id":"PMC_30543861","title":"The effects of IKK-beta inhibition on early NF-kappa-B activation and transcription of downstream genes.","date":"2018","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/30543861","citation_count":28,"is_preprint":false},{"pmid":"19348415","id":"PMC_19348415","title":"Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta).","date":"2009","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19348415","citation_count":28,"is_preprint":false},{"pmid":"17330097","id":"PMC_17330097","title":"AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.","date":"2007","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/17330097","citation_count":28,"is_preprint":false},{"pmid":"21469085","id":"PMC_21469085","title":"IKK-β-mediated myeloid cell activation exacerbates inflammation and inhibits recovery after spinal cord injury.","date":"2011","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21469085","citation_count":27,"is_preprint":false},{"pmid":"24618907","id":"PMC_24618907","title":"Constitutive activation of IKK2/NF-κB impairs osteogenesis and skeletal development.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24618907","citation_count":27,"is_preprint":false},{"pmid":"25036911","id":"PMC_25036911","title":"Rosiglitazone inhibits hepatic insulin resistance induced by chronic pancreatitis and IKK-β/NF-κB expression in liver.","date":"2014","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/25036911","citation_count":27,"is_preprint":false},{"pmid":"27082459","id":"PMC_27082459","title":"Activation of G-Protein-Coupled Estrogen Receptor Inhibits the Migration of Human Nonsmall Cell Lung Cancer Cells via IKK-β/NF-κB Signals.","date":"2016","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27082459","citation_count":27,"is_preprint":false},{"pmid":"32019925","id":"PMC_32019925","title":"A central role of IKK2 and TPL2 in JNK activation and viral B-cell transformation.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32019925","citation_count":26,"is_preprint":false},{"pmid":"31894515","id":"PMC_31894515","title":"Therapeutic potential of IKK-β inhibitors from natural phenolics for inflammation in cardiovascular diseases.","date":"2020","source":"Inflammopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31894515","citation_count":26,"is_preprint":false},{"pmid":"28708489","id":"PMC_28708489","title":"2-Methoxystypandrone improves in vitro-produced bovine embryo quality through inhibition of IKBKB.","date":"2017","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/28708489","citation_count":26,"is_preprint":false},{"pmid":"15039214","id":"PMC_15039214","title":"IKK2 inhibitor alleviates kidney and wasting diseases in a murine model of human AIDS.","date":"2004","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15039214","citation_count":26,"is_preprint":false},{"pmid":"16239395","id":"PMC_16239395","title":"IKK{beta} as a target for treatment of inflammation induced bone loss.","date":"2005","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/16239395","citation_count":26,"is_preprint":false},{"pmid":"24489934","id":"PMC_24489934","title":"IKK2 inhibition attenuates laser-induced choroidal neovascularization.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24489934","citation_count":25,"is_preprint":false},{"pmid":"37199240","id":"PMC_37199240","title":"Microglia-specific knock-out of NF-κB/IKK2 increases the accumulation of misfolded α-synuclein through the inhibition of p62/sequestosome-1-dependent autophagy in the rotenone model of Parkinson's disease.","date":"2023","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/37199240","citation_count":25,"is_preprint":false},{"pmid":"25355930","id":"PMC_25355930","title":"The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-κB.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25355930","citation_count":24,"is_preprint":false},{"pmid":"33542074","id":"PMC_33542074","title":"Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies.","date":"2021","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/33542074","citation_count":22,"is_preprint":false},{"pmid":"26378659","id":"PMC_26378659","title":"Mutation of cysteine 46 in IKK-beta increases inflammatory responses.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26378659","citation_count":22,"is_preprint":false},{"pmid":"30130718","id":"PMC_30130718","title":"Design, synthesis and biological evaluation of novel thiazolidinedione derivatives as irreversible allosteric IKK-β modulators.","date":"2018","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30130718","citation_count":22,"is_preprint":false},{"pmid":"32434006","id":"PMC_32434006","title":"Emerging role of NIK/IKK2-binding protein (NIBP)/trafficking protein particle complex 9 (TRAPPC9) in nervous system diseases.","date":"2020","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32434006","citation_count":21,"is_preprint":false},{"pmid":"22313691","id":"PMC_22313691","title":"IKK-β mediates chemoresistance by sequestering FOXO3; a critical factor for cell survival and death.","date":"2012","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/22313691","citation_count":21,"is_preprint":false},{"pmid":"21357939","id":"PMC_21357939","title":"Hepatocyte-specific IKK-β activation enhances VLDL-triglyceride production in APOE*3-Leiden mice.","date":"2011","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/21357939","citation_count":21,"is_preprint":false},{"pmid":"25107905","id":"PMC_25107905","title":"IκB kinase β (IKBKB) mutations in lymphomas that constitutively activate canonical nuclear factor κB (NFκB) signaling.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25107905","citation_count":20,"is_preprint":false},{"pmid":"24011459","id":"PMC_24011459","title":"Expression and function of NIK- and IKK2-binding protein (NIBP) in mouse enteric nervous system.","date":"2013","source":"Neurogastroenterology and motility","url":"https://pubmed.ncbi.nlm.nih.gov/24011459","citation_count":20,"is_preprint":false},{"pmid":"22955948","id":"PMC_22955948","title":"IKK-β mediates hydrogen peroxide induced cell death through p85 S6K1.","date":"2012","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/22955948","citation_count":20,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51651,"output_tokens":8703,"usd":0.142749,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18835,"output_tokens":5722,"usd":0.118612,"stage2_stop_reason":"end_turn"},"total_usd":0.261361,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"IKK-beta (IKK-2/IKBKB) was identified as a catalytic subunit of the large IKK signalsome complex purified from HeLa cells. It phosphorylates IκBα and IκBβ in a cytokine-inducible manner, and dominant-negative mutants of IKK-2 blocked RelA nuclear translocation and NF-κB-dependent reporter activity, establishing IKK-2 as a critical kinase in the NF-κB signaling pathway.\",\n      \"method\": \"Biochemical purification of IKK signalsome from HeLa cells; in vitro kinase assay; dominant-negative mutant overexpression; NF-κB reporter assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical purification, in vitro kinase assay, and dominant-negative mutagenesis in the founding paper; widely replicated\",\n      \"pmids\": [\"9346484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IKK-beta-deficient mice die at ~E14.5 due to liver degeneration and apoptosis. IKK-beta-deficient embryonic fibroblasts show reduced basal NF-κB activity and impaired cytokine-induced NF-κB activation, and the IKK complex has greatly reduced basal and cytokine-inducible kinase activity. IKK-alpha can only partially compensate for loss of IKK-beta in vivo.\",\n      \"method\": \"Germline gene knockout in mice; kinase activity assays on IKK complex from KO fibroblasts; NF-κB activity assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype, kinase activity assays, replicated by multiple subsequent studies\",\n      \"pmids\": [\"10229185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The recombinant IKK1/IKK2 heterodimer has the highest catalytic efficiency (kcat/Km = 47.50 h⁻¹ μM⁻¹) for phosphorylating an IκBα peptide substrate among all IKK isoforms tested. IKK2 homodimer is more active than IKK1 homodimer. Activation loop phosphorylation (mimicked by S177E/S181E mutation) regulates kinase activity; ADP acts as a competitive inhibitor with Ki = 0.77 μM.\",\n      \"method\": \"Baculoviral expression, purification, and in vitro kinetic characterization of recombinant IKK1/IKK2 heterodimer, homodimers, and constitutively active mutant; IκBα peptide substrate kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified recombinant protein, kinetic analysis, and mutagenesis in a single rigorous study\",\n      \"pmids\": [\"10823818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Epidermis-specific deletion of IKK2 inhibits NF-κB activation in keratinocytes and causes a severe TNF-mediated, αβ T-cell-independent inflammatory skin disease, demonstrating that IKK2-mediated NF-κB activity in epidermal keratinocytes is required for maintaining skin immune homeostasis.\",\n      \"method\": \"Cre/loxP conditional knockout of IKK2 in epidermal keratinocytes; histological and immunological analysis of skin phenotype\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined cellular phenotype and mechanistic follow-up identifying TNF as mediator; published in high-impact journal\",\n      \"pmids\": [\"12075355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IKK-beta plays an essential role in LPS-induced phosphorylation of RelA/p65 at serine 536, promoting NF-κB transcriptional activity. IKK-alpha only partially contributes to this phosphorylation. This phosphorylation is independent of the PI3K/Akt pathway.\",\n      \"method\": \"Mouse embryonic fibroblasts lacking IKK-alpha or IKK-beta; Western blot for p65 Ser536 phosphorylation; reporter assays; LPS stimulation\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO MEFs with defined biochemical readout; two orthogonal methods (Western blot + reporter assay)\",\n      \"pmids\": [\"12759443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IKK-beta is required for peripheral B cell survival and proliferation. Conditional deletion of IKKbeta in B cells dramatically reduces all peripheral B cell subsets due to cell survival defects, impairs mitogenic responses to LPS, anti-CD40, and anti-IgM, and blocks canonical NF-κB signaling, resulting in failure to mount effective antibody responses.\",\n      \"method\": \"Conditional KO mice with floxed Ikkbeta allele; flow cytometry; B cell survival and proliferation assays; NF-κB signaling assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with multiple defined phenotypic readouts; clean mechanistic follow-up\",\n      \"pmids\": [\"12707341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Multiple kinases including IKK-alpha, IKKbeta, IKKε, and TBK1 can phosphorylate p65 at Ser536. IKKε and TBK1 phosphorylate Ser536 in vivo and in vitro. Ser536 phosphorylation promotes IL-8 transcription mediated by TAF(II)31 recruitment to the promoter; absence of phosphorylation favors binding of the corepressor AES to p65.\",\n      \"method\": \"RNA interference; chromatographic fractionation; dominant-negative mutants; in vitro kinase assay; reconstitution in p65-deficient fibroblasts with phosphomimetic/phosphoblocking mutants; reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assays, in vivo reconstitution with mutagenesis, and multiple orthogonal methods in one study\",\n      \"pmids\": [\"15489227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IKK-beta is activated in liver by obesity/high-fat diet, and selective hepatocyte-specific constitutive activation of IKK-beta (LIKK mice) causes a type 2 diabetes phenotype with hyperglycemia, hepatic insulin resistance, and systemic insulin resistance via production of proinflammatory cytokines (IL-6, IL-1β, TNF-α). IκBα superrepressor expression in hepatocytes reversed both LIKK and HFD-induced phenotypes. Salicylate inhibition of IKK-beta or IL-6 neutralization improved insulin resistance.\",\n      \"method\": \"Transgenic mice with constitutively active IKK-beta in hepatocytes; IκBα superrepressor transgenic mice; cytokine neutralization; salicylate pharmacology; glucose/insulin tolerance tests\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models, pharmacological rescue, and cytokine neutralization; replicated across labs\",\n      \"pmids\": [\"15685173\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IKK-beta in myeloid cells activates NF-κB to produce inflammatory mediators that cause systemic insulin resistance. Myeloid-specific IKK-beta knockout mice (Ikbkb∆mye) are protected from high-fat diet, obesity, or aging-induced insulin resistance, whereas hepatocyte-specific knockout (Ikbkb∆hep) retains liver insulin sensitivity but develops peripheral insulin resistance.\",\n      \"method\": \"Conditional KO mice with myeloid-specific or hepatocyte-specific deletion of Ikbkb; high-fat diet and aging models; insulin sensitivity assays\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple conditional KO models with defined metabolic phenotypes; replicated independently of PMID:15685173\",\n      \"pmids\": [\"15685170\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PDK1 directly phosphorylates IKKbeta at Ser181 in the activation loop, leading to NF-κB nuclear translocation and NF-κB-dependent anti-apoptotic gene expression. This is independent of Akt and IKKα, and constitutively active IKKbeta rescues cells from PDK1 knockdown-mediated TRAIL sensitization.\",\n      \"method\": \"Kinase screen; in vitro phosphorylation assay; site-specific mutants; IKKα-KO MEFs; siRNA knockdown; NF-κB reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro kinase assay with site identification, but single lab and limited mutagenesis validation described in abstract\",\n      \"pmids\": [\"16207722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IKK-beta is required for Bcl-2-mediated NF-κB activation in ventricular myocytes. Bcl-2 increases IKK-beta kinase activity (requiring the BH4 domain), and catalytically inactive IKK-beta (but not IKK-alpha) blocks Bcl-2-mediated IκBα phosphorylation and NF-κB activation. This mechanism involves Raf-1/MEKK-1-mediated activation of IKK-beta.\",\n      \"method\": \"Overexpression of Bcl-2 mutants in ventricular myocytes; kinase activity assay; dominant-negative IKK-beta/alpha; IKKbeta-null MEFs; kinase-defective Raf-1/MEKK-1 mutants\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — kinase activity assay plus KO MEFs and multiple dominant-negatives, single lab\",\n      \"pmids\": [\"12167626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"NIBP (NIK and IKKbeta-binding protein) physically interacts with NIK and IKK-beta but not IKK-alpha or IKK-gamma. NIBP overexpression potentiates TNF-α-induced NF-κB activation through increased phosphorylation of the IKK complex, IκBα, and p65, while NIBP knockdown reduces TNF-α-induced NF-κB activation.\",\n      \"method\": \"Yeast two-hybrid screen; co-immunoprecipitation; overexpression and siRNA knockdown; NF-κB reporter assay; Western blot for IKK complex phosphorylation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP binding confirmed, functional effects validated by OE and KD, single lab\",\n      \"pmids\": [\"15951441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IKKbeta physically interacts with TSC1 and phosphorylates it at Ser487 and Ser511, suppressing the TSC1/TSC2 tumor suppressor complex, which activates the mTOR pathway and enhances tumor angiogenesis via VEGF production.\",\n      \"method\": \"Co-immunoprecipitation; in vitro kinase assay with site-specific phosphorylation; mutant TSC1 overexpression; in vivo tumor models; IHC of tumor specimens for Ser511 phosphorylation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro phosphorylation assay with identified phosphosites, co-IP, and in vivo validation in a high-impact journal\",\n      \"pmids\": [\"17693255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"IEC-intrinsic IKKbeta-dependent gene expression controls intestinal immune homeostasis. IEC-specific IKKbeta deletion reduces epithelial TSLP expression, impairs CD4+ Th2 responses to Trichuris infection, and leads to exacerbated DC-derived IL-12/23p40 and TNF-α and CD4+ T cell-derived IFN-γ and IL-17, causing severe intestinal inflammation.\",\n      \"method\": \"Cre/loxP conditional KO of IKKbeta in intestinal epithelial cells; parasite infection model; cytokine blockade experiments; T cell transfer\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with multiple defined cellular phenotypes and cytokine blockade rescue; published in Nature\",\n      \"pmids\": [\"17322906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Constitutive activation of IKK2 in pancreatic acinar cells is sufficient to induce acute pancreatitis in vivo, including edema, inflammatory infiltrates, necrosis, elevated serum lipase, and fibrosis. Dominant-negative IKK2 ameliorated cerulein-induced pancreatitis. TNF-α was identified as a critical effector of IKK2-induced pancreatitis.\",\n      \"method\": \"Tetracycline-inducible acinar cell-specific expression of constitutively active or dominant-negative IKK2 in transgenic mice; cerulein pancreatitis model; TNF-α inhibition\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional gain- and loss-of-function in same tissue with defined phenotypic outcomes and mechanistic rescue\",\n      \"pmids\": [\"17525799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IKK1 and IKK2 display distinct collaborative and redundant functions in the liver. Combined conditional ablation of both IKK1 and IKK2 (but not each alone) sensitizes hepatocytes to TNF-induced failure and causes spontaneous fatal cholangitis with inflammatory bile duct destruction. IKK2 alone does not mediate canonical NF-κB in hepatocytes upon TNF stimulation (unlike NEMO), but combined IKK1+IKK2 ablation uncovered redundancy in canonical NF-κB and IKK1-specific functions maintaining bile-blood barrier.\",\n      \"method\": \"Conditional (hepatocyte-specific) combined KO of IKK1, IKK2, or NEMO; LPS challenge; histological analysis; NF-κB activation assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple conditional KO combinations with clear phenotypic epistasis; mechanistic dissection of redundancy\",\n      \"pmids\": [\"18606991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Ro52 (an E3 ubiquitin ligase) interacts with phosphorylated/active IKKbeta and, cooperating with the E2 enzyme UbcH5B, monoubiquitinates IKKbeta. This monoubiquitination down-regulates IKKbeta-induced NF-κB signaling and promotes translocation of active IKKbeta to autophagosomes for degradation.\",\n      \"method\": \"Co-immunoprecipitation; in vitro ubiquitination assay; NF-κB reporter assay; monoubiquitin fusion protein; autophagy inhibitor treatment; subcellular localization imaging\",\n      \"journal\": \"Journal of biochemistry; Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus in vitro ubiquitination and functional reporter assays; two papers from the same lab\",\n      \"pmids\": [\"19675099\", \"20627395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PP2A constitutively dephosphorylates and inactivates IKKbeta; UVB irradiation inhibits PP2Ac activity, preventing IKKbeta dephosphorylation and causing persistent IKKbeta activation that phosphorylates newly synthesized IκBα, sustaining NF-κB activation.\",\n      \"method\": \"Mathematical modeling combined with experimental validation; PP2A activity assays; IKKbeta phosphorylation kinetics; IL-1 and UVB stimulation of cells\",\n      \"journal\": \"BMC systems biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — experimental-modeling integrated approach; mechanistic identification of PP2A as IKKbeta phosphatase; single lab\",\n      \"pmids\": [\"19607706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IKK-beta is required in B cells for NF-κB activation and in response to LPS in monocytic cells. A dominant-negative IKK2 mutant, but not wild-type IKK1 or IKK2, inhibited LPS-induced κB-dependent transcription in a dose-dependent manner in human monocytic cells.\",\n      \"method\": \"Dominant-negative IKK2 overexpression in monocytic cells; κB-dependent reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — dominant-negative approach with functional reporter readout; replicated across multiple labs in different cell types\",\n      \"pmids\": [\"9804806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"IKK-beta is required for activation of both IRF1 and p65 subunit of NF-κB in response to IFN-γ, revealing a novel role for IKKbeta in IFN-γ-dependent chemokine (ip-10) gene expression independent of classical NF-κB activation.\",\n      \"method\": \"IKKbeta-deficient MEFs; ChIP; reporter assays; IFN-γ and IL-1β stimulation\",\n      \"journal\": \"Journal of interferon & cytokine research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic KO MEFs with defined molecular readout; single lab, single paper\",\n      \"pmids\": [\"19929594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IKKbeta directly phosphorylates and activates TSC1 suppression to activate mTOR. In lung cancer, IKK2 promotes tumor proliferation via NF-κB target gene Timp1, which activates the Erk signaling pathway through its receptor CD63. IKK2 depletion reduced tumor proliferation and prolonged survival in a lentiviral lung cancer model.\",\n      \"method\": \"Lentiviral shRNA knockdown of Ikbkb in mouse lung cancer model; xenograft and lentiviral tumor models; identification of Timp1 as NF-κB target mediator\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo lentiviral KD model with survival readout and mechanistic target identification; single lab\",\n      \"pmids\": [\"22327365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IKK-beta directly interacts with and sequesters FOXO3 in the cytosol, preventing FOXO3 nuclear localization and thereby promoting chemoresistance to cisplatin in MDA-MB-231 breast cancer cells.\",\n      \"method\": \"Co-immunoprecipitation; overexpression and RNAi knockdown; subcellular fractionation; apoptosis assays\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP interaction plus functional subcellular localization assay and rescue experiments; single lab\",\n      \"pmids\": [\"22313691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KrasG12D activates AP-1 to induce IL-1α, which in turn activates IKK2/β-NF-κB; NF-κB then induces IL-1α and p62 as feedforward loops sustaining NF-κB activity. Pancreas-targeted IKK2/β inactivation inhibited NF-κB and PDAC development in KrasG12D mice.\",\n      \"method\": \"Conditional pancreatic IKK2 inactivation in KrasG12D mouse models; analysis of IL-1α/p62 feedforward loops; gene expression and NF-κB activity assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo with mechanistic dissection of feedforward loops; published in Cancer Cell\",\n      \"pmids\": [\"22264792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"IKK-beta contributes to H2O2-induced cell death independent of NF-κB, via p85 S6K1. IKK-beta associates with p85 (but not p70) S6K1, which is required for H2O2-induced p85 S6K1 activation, leading to Mdm2 Ser166 phosphorylation and p53 accumulation.\",\n      \"method\": \"Co-immunoprecipitation; kinase activity assay; siRNA knockdown; phospho-specific Western blot; cell death assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP plus functional rescue; NF-κB-independent mechanism established; single lab\",\n      \"pmids\": [\"22955948\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Hypothalamic IKK-β and NF-κB inhibit GnRH production to mediate aging-related GnRH decline. Prevention of hypothalamic IKK-β and NF-κB activation retards aging and extends lifespan in mice. GnRH treatment amends aging-impaired neurogenesis.\",\n      \"method\": \"Conditional IKK-β activation/inhibition in hypothalamus using viral vectors; GnRH measurement; lifespan and neurogenesis assays; transgenic mouse models\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple interventional models, mechanistic pathway identification (IKK-β→NF-κB→GnRH suppression), published in Nature\",\n      \"pmids\": [\"23636330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Loss-of-function IKBKB mutation (c.1292dupG) in humans causes severe combined immunodeficiency with loss of IKK2 expression, resulting in impaired responses to stimulation through T-cell receptors, B-cell receptors, toll-like receptors, inflammatory cytokine receptors, and mitogens in multiple immune cell types.\",\n      \"method\": \"Homozygosity mapping; whole gene sequencing; functional immune cell stimulation assays; patient lymphocyte studies\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human loss-of-function genetics with comprehensive multi-receptor functional validation in patient cells\",\n      \"pmids\": [\"24369075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A nonsense mutation in IKBKB (R286X) causes combined immunodeficiency in humans. Mutant IKKβ(R286X) is unable to complex with IKKα/NEMO, leading to impaired IκBα phosphorylation and NF-κB nuclear translocation in patient B cells.\",\n      \"method\": \"Whole-exome sequencing; co-immunoprecipitation to test complex formation; Western blot for IκBα phosphorylation; immunofluorescence for NF-κB nuclear translocation\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human genetics with co-IP, biochemical, and cell-biological mechanistic validation; multi-family study\",\n      \"pmids\": [\"25139357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IKKβ K171E and K171T mutations found in lymphomas result in constitutively active kinase even in the absence of activation loop phosphorylation. Lysine 171 normally forms part of a cationic pocket interacting with the activation loop phosphate; its mutation disrupts this interaction, causing constitutive activity and contributing to lymphomagenesis.\",\n      \"method\": \"Biochemical kinase activity assays; predictive structural modeling; TALEN-based knock-in mutagenesis in B lymphoid cells; NF-κB signaling assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay, mutagenesis, structural modeling, and knock-in functional validation in a single study\",\n      \"pmids\": [\"25107905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Cysteine-46 (Cys-46) is an essential residue for IKK-β kinase activity. Mutation of Cys-46 to alanine (C46A) increases inflammatory responses in vivo in a DTH mouse model. Dihydromyricetin (DMY) binds Cys-46 to exert anti-inflammatory effects in WT but not C46A transgenic mice.\",\n      \"method\": \"In vitro mutagenesis of IKK-β; C46A transgenic mouse model; delayed-type hypersensitivity model; IKK-β kinase activity assay; pharmacological challenge\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro mutagenesis with in vivo validation in transgenic mouse; mechanistic drug binding site identified; single lab\",\n      \"pmids\": [\"26378659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A de novo heterozygous gain-of-function IKBKB missense mutation (V203I) causes enhanced NF-κB signaling and combined T and B cell functional defects in humans. CRISPR/Cas9 knock-in of the orthologous codon change in mice recapitulates the human cellular and biochemical phenotype, establishing causation.\",\n      \"method\": \"Whole exome sequencing; NF-κB signaling assays in patient cells; CRISPR/Cas9 knock-in mouse model; T and B cell functional assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetics with CRISPR knock-in mouse validation recapitulating phenotype; two independent kindreds\",\n      \"pmids\": [\"30337470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IKK2 mediates LMP1 (Epstein-Barr virus)-induced JNK activation independently of its canonical NF-κB function. LMP1 induces TAK1-mediated NEMO ubiquitination and IKK2 activation, which then activates TPL2 kinase to transmit JNK activation signals. This IKK2-TPL2-JNK axis mediates essential LMP1 survival signals in EBV-transformed B cells.\",\n      \"method\": \"Genetic knockdown/overexpression; co-immunoprecipitation; kinase activity assays; EBV-transformed B cell models; lymphoma cell line studies\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, kinase assays, and genetic rescue in EBV-transformed cells; identifies a novel IKK2 substrate (TPL2) in JNK pathway\",\n      \"pmids\": [\"32019925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Paclitaxel activates IKK2 through TLR4 signaling, and IKK2 mediates SNARE-dependent vesicle exocytosis to expose calreticulin on the cell surface, contributing to immunogenic cell death (ICD) in ovarian cancer. This is mechanistically distinct from paclitaxel-induced ER stress signaling.\",\n      \"method\": \"TLR4 inhibition; IKK2 knockdown; SNARE pathway analysis; CALR surface exposure assay; tumor vaccination assay in vivo\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological dissection of TLR4-IKK2-SNARE pathway with in vitro and in vivo functional assays; single lab\",\n      \"pmids\": [\"32354736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Deletion of IKK2 specifically in hepatocytes does not impair NF-κB activation or increase apoptosis after TNF-α stimulation (unlike NEMO deletion which blocks NF-κB and causes massive apoptosis), but does protect from ischemia/reperfusion injury.\",\n      \"method\": \"Conditional hepatocyte-specific KO of IKK2 or NEMO; TNF-α challenge; partial hepatic I/R injury model; NF-κB activation assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with direct comparison to NEMO KO, rigorous biochemical and phenotypic readouts; establishes IKK2 dispensability for hepatocyte NF-κB after TNF\",\n      \"pmids\": [\"15776110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Muscle-restricted deletion of IKK2 shifts muscle fiber distribution, improves muscle force, protects against denervation-induced atrophy (maintaining fiber type, size, and strength), and facilitates skeletal muscle regeneration through enhanced satellite cell activation and reduced fibrosis.\",\n      \"method\": \"Conditional muscle-specific KO of IKK2; denervation model; muscle damage/regeneration model; force measurement; protein synthesis/degradation assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with multiple defined functional and molecular phenotypes; mechanistic protein synthesis/degradation readouts\",\n      \"pmids\": [\"17080195\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IKBKB (IKK-beta/IKK2) is the primary catalytic serine/threonine kinase subunit of the IKK signalsome complex that phosphorylates IκBα/β at specific serines to trigger their ubiquitination and proteasomal degradation, releasing and activating NF-κB transcription factors; beyond canonical IκB phosphorylation, IKKbeta directly phosphorylates additional substrates including TSC1 (activating mTOR), p85 S6K1 (mediating oxidative stress-induced cell death), and p65/RelA at Ser536 (enhancing transcriptional activity), is itself regulated by upstream kinases (PDK1 phosphorylates Ser181) and by Ro52-mediated monoubiquitination directing it to autophagosomal degradation, and has essential tissue-specific roles in B and T cell activation, skin and intestinal immune homeostasis, hepatic and systemic metabolic regulation, muscle homeostasis, and hypothalamic control of aging and blood pressure—all operating primarily, though not exclusively, through NF-κB-dependent transcription.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IKBKB (IKK-beta/IKK2) is the principal catalytic serine/threonine kinase of the multiprotein IKK signalsome that drives canonical NF-κB activation by phosphorylating IκBα and IκBβ in a cytokine-inducible manner, triggering their degradation and releasing RelA for nuclear translocation [#0]. It is the dominant catalytic isoform: the IKK1/IKK2 heterodimer is the most kinetically efficient configuration for IκBα phosphorylation, its activity is gated by activation-loop phosphorylation at Ser177/Ser181, and germline loss causes embryonic lethality from hepatic apoptosis with only partial compensation by IKK-alpha [#1, #2]. Beyond IκB, IKK2 amplifies NF-κB output by directly phosphorylating RelA/p65 at Ser536 to promote coactivator recruitment and transcription [#4, #6], and it extends into NF-κB-independent signaling by phosphorylating TSC1 (at Ser487/Ser511) to activate mTOR and angiogenesis [#12], by associating with p85 S6K1 to drive H2O2-induced p53-dependent death [#23], and by activating a TPL2-JNK survival axis downstream of EBV LMP1 [#30]. Its activity is set by upstream kinases including PDK1 (Ser181) [#9] and constrained by PP2A-mediated dephosphorylation [#17] and Ro52-mediated monoubiquitination that targets active IKK2 to autophagosomes [#16]. Tissue-restricted genetic studies establish non-redundant roles in epidermal and intestinal immune homeostasis [#3, #13], peripheral B-cell survival [#5], hepatic and myeloid-driven metabolic control of insulin resistance [#7, #8], skeletal muscle homeostasis [#33], and hypothalamic NF-κB control of GnRH and aging [#24], while constitutive IKK2 activity contributes to pancreatitis and Kras-driven and lymphoid malignancy [#14, #22, #27]. In humans, both loss-of-function and gain-of-function IKBKB mutations cause combined immunodeficiency, directly linking IKK2 kinase activity and complex assembly to immune cell signaling [#25, #26, #29].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that IKK2 is a catalytic kinase subunit physically driving cytokine-induced NF-κB activation, defining the core of the canonical pathway.\",\n      \"evidence\": \"Biochemical purification of the IKK signalsome from HeLa cells with in vitro kinase assays and dominant-negative mutants\",\n      \"pmids\": [\"9346484\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve isoform-specific contributions of IKK1 vs IKK2\", \"Upstream activating kinases not yet defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrated IKK2 is non-redundant in vivo for NF-κB-dependent hepatocyte survival, showing IKK-alpha cannot fully compensate.\",\n      \"evidence\": \"Germline knockout mice with kinase activity and NF-κB assays in KO fibroblasts\",\n      \"pmids\": [\"10229185\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Embryonic lethality precluded analysis of adult tissue-specific roles\", \"Mechanism of partial IKK-alpha compensation unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Quantified the biochemical basis for IKK2 dominance by showing the IKK1/IKK2 heterodimer is the most efficient IκBα kinase and that activation-loop phosphorylation governs activity.\",\n      \"evidence\": \"Recombinant baculoviral expression and in vitro kinetic characterization with phosphomimetic mutants\",\n      \"pmids\": [\"10823818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetics on peptide substrate may not reflect full-length IκB or in-cell regulation\", \"Did not address substrates beyond IκBα\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Extended IKK2 function beyond IκB to direct phosphorylation of RelA/p65 at Ser536, showing it shapes NF-κB transcriptional output, not just nuclear entry.\",\n      \"evidence\": \"IKK-alpha/IKK-beta KO MEFs with phospho-specific Western blot and reporter assays under LPS stimulation\",\n      \"pmids\": [\"12759443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of multiple Ser536 kinases not resolved\", \"Promoter-context dependence not addressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Clarified the transcriptional consequence of Ser536 phosphorylation by linking it to coactivator (TAF II 31) versus corepressor (AES) recruitment at target promoters.\",\n      \"evidence\": \"RNAi, in vitro kinase assays, and reconstitution of p65-deficient fibroblasts with phosphomimetic/blocking mutants plus reporter assays\",\n      \"pmids\": [\"15489227\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Multiple kinases (IKKε, TBK1) also phosphorylate Ser536, complicating IKK2-specific attribution\", \"Genome-wide target scope not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined upstream and counter-regulatory inputs on IKK2 activity: PDK1 phosphorylates Ser181 to promote survival signaling, and converging Raf-1/MEKK-1 and Bcl-2 inputs activate IKK2.\",\n      \"evidence\": \"Kinase screens, in vitro phosphorylation, site-specific and dominant-negative mutants, IKKα-KO MEFs, and ventricular myocyte overexpression\",\n      \"pmids\": [\"16207722\", \"12167626\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"PDK1-IKK2 link based on a single lab with limited mutagenesis\", \"Physiological context of Bcl-2-IKK2 coupling beyond myocytes unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established IKK2 as a central node coupling inflammation to metabolic disease, with distinct hepatocyte- versus myeloid-intrinsic contributions to insulin resistance.\",\n      \"evidence\": \"Hepatocyte-constitutive-active, hepatocyte-KO, and myeloid-KO mouse models with IκBα superrepressor rescue, cytokine neutralization, and salicylate pharmacology\",\n      \"pmids\": [\"15685173\", \"15685170\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct metabolic substrates of IKK2 distinct from NF-κB cytokine output not defined\", \"Relative cross-tissue weighting in human disease not addressed\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified phosphatase and adaptor control of IKK2: PP2A constitutively inactivates IKK2 and is itself suppressed by UVB to sustain signaling, while NIBP potentiates IKK complex phosphorylation.\",\n      \"evidence\": \"PP2A activity assays with modeling, IL-1/UVB stimulation, and yeast two-hybrid plus Co-IP/knockdown for NIBP\",\n      \"pmids\": [\"19607706\", \"15951441\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NIBP interaction validated in a single lab without reciprocal in vivo evidence\", \"PP2A regulation studied via modeling-experiment integration in limited cell contexts\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Uncovered the first major NF-κB-independent substrate axis by showing IKK2 phosphorylates TSC1 (Ser487/Ser511) to suppress the TSC complex and activate mTOR, linking inflammation to growth and angiogenesis.\",\n      \"evidence\": \"Co-IP, in vitro kinase assays with phosphosite identification, mutant overexpression, in vivo tumor models, and tumor IHC\",\n      \"pmids\": [\"17693255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of TSC1 phosphorylation to mTOR activity in normal tissues unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated tissue-intrinsic IKK2 requirements for epithelial immune homeostasis in intestine and the sufficiency of IKK2 activation to drive pancreatitis.\",\n      \"evidence\": \"Intestinal epithelial and pancreatic acinar conditional gain/loss-of-function mouse models with infection, cytokine blockade, and cerulein challenge\",\n      \"pmids\": [\"17322906\", \"17525799\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream IKK2-dependent gene programs only partially mapped\", \"TNF identified as effector but full mediator network undefined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Dissected hepatic IKK isoform logic, showing IKK2 alone is dispensable for hepatocyte canonical NF-κB after TNF but redundant with IKK1, which maintains the bile-blood barrier.\",\n      \"evidence\": \"Combined and single hepatocyte-specific conditional KO of IKK1, IKK2, and NEMO with LPS challenge and histology\",\n      \"pmids\": [\"18606991\", \"15776110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of IKK1/IKK2 redundancy in hepatocytes not defined\", \"Substrate-level explanation for NEMO vs IKK2 divergence unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a degradative off-switch in which Ro52, with UbcH5B, monoubiquitinates active IKK2 to dampen NF-κB and route it to autophagosomes.\",\n      \"evidence\": \"Co-IP, in vitro ubiquitination, monoubiquitin fusions, autophagy inhibition, and localization imaging\",\n      \"pmids\": [\"19675099\", \"20627395\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Both reports from the same lab\", \"Physiological triggers controlling Ro52-IKK2 engagement unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Broadened IKK2 effector outputs beyond IκB to FOXO3 cytosolic sequestration, p85-S6K1-driven oxidative death, and Kras-NF-κB feedforward loops sustaining tumorigenesis.\",\n      \"evidence\": \"Co-IP, knockdown/overexpression, subcellular fractionation, kinase assays, and conditional pancreatic IKK2 inactivation in KrasG12D mice\",\n      \"pmids\": [\"22313691\", \"22955948\", \"22264792\", \"22327365\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"FOXO3 and S6K1 interactions rest on single-lab Co-IP without structural detail\", \"Direct vs indirect nature of several effector links not fully separated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed a systemic physiological role for hypothalamic IKK-β/NF-κB in suppressing GnRH to drive aging, identifying it as a modulator of lifespan and neurogenesis.\",\n      \"evidence\": \"Viral hypothalamic IKK-β activation/inhibition, transgenic mice, GnRH measurement, and lifespan/neurogenesis assays\",\n      \"pmids\": [\"23636330\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link from NF-κB to GnRH repression not defined\", \"Neuronal-specific IKK2 substrates unidentified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established human IKBKB disease causation through loss-of-function mutations causing combined immunodeficiency via failed complex assembly and impaired IκBα phosphorylation.\",\n      \"evidence\": \"Whole-exome sequencing, Co-IP for complex formation, IκBα phospho-blots, and NF-κB translocation in patient cells\",\n      \"pmids\": [\"24369075\", \"25139357\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype range across mutation types incompletely mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Defined structural determinants of IKK2 catalysis by showing K171 mutations disrupt activation-loop phosphate coordination to yield constitutive, oncogenic kinase activity.\",\n      \"evidence\": \"Biochemical kinase assays, structural modeling, and TALEN knock-in in B lymphoid cells\",\n      \"pmids\": [\"25107905\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of the mutant confirming the proposed cationic pocket\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated that gain-of-function IKBKB mutation causes human immune disease through enhanced NF-κB signaling, formally proving causation in vivo.\",\n      \"evidence\": \"Whole-exome sequencing, patient-cell NF-κB assays, and CRISPR/Cas9 knock-in mice recapitulating phenotype\",\n      \"pmids\": [\"30337470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which V203I enhances activity at the structural level not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Expanded IKK2 signaling repertoire to NF-κB-independent outputs: a TPL2-JNK survival axis downstream of EBV LMP1 and SNARE-dependent calreticulin exposure for immunogenic cell death.\",\n      \"evidence\": \"Co-IP, kinase assays, genetic rescue in EBV-transformed B cells, and TLR4/IKK2/SNARE dissection with CALR surface assays\",\n      \"pmids\": [\"32019925\", \"32354736\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IKK2 substrate in the SNARE/exocytosis pathway not identified\", \"Generality of IKK2-TPL2-JNK axis beyond EBV context unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How IKK2 substrate selection is partitioned between canonical IκB/NF-κB signaling and the growing set of NF-κB-independent substrates (TSC1, S6K1, TPL2, FOXO3) in a context-dependent manner remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model for substrate switching\", \"Stoichiometry and structural basis of non-canonical substrate engagement undefined\", \"In vivo relevance of several effector axes outside disease models untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 4, 12, 23]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 12, 27]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 4, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [21, 23]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 9, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 5, 13, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 4, 6]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [22, 25, 27, 29]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [7, 8]}\n    ],\n    \"complexes\": [\"IKK signalsome (IKK complex)\"],\n    \"partners\": [\"IKBKA\", \"IKBKG\", \"NIK\", \"TSC1\", \"RPS6KB1\", \"FOXO3\", \"NIBP\", \"TRIM21\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}